• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Taysha Gene Therapies Inc.

    11/14/24 5:51:11 PM ET
    $TSHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $TSHA alert in real time by email
    SC 13G/A 1 tm2428137d16_sc13ga.htm SC 13G/A

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G/A

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 2)*

     

    Taysha Gene Therapies, Inc.

    (Name of Issuer)

     

    Common stock, par value $0.00001 per share

    (Title of Class of Securities)

     

    877619106

    (CUSIP Number)

     

    September 30, 2024

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨Rule 13d-1(b)

     

    xRule 13d-1(c)

     

    ¨Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

    CUSIP No. 877619106 Page 2 of 14

     

    1.

    Names of Reporting Persons

    Venrock Healthcare Capital Partners III, L.P.

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) x (1)  (b) ¨

    3. SEC Use Only
    4.

    Citizenship or Place of Organization

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    5.

    Sole Voting Power

    0

    6.

    Shared Voting Power

    9,000,000 (2)

    7.

    Sole Dispositive Power

    0

    8.

    Shared Dispositive Power

    9,000,000 (2)

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

    9,000,000 (2)

    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨
    11.

    Percent of Class Represented by Amount in Row (9)

    4.4% (3)

    12.

    Type of Reporting Person (See Instructions)

    PN

           

    (1)Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G/A.

     

    (2)Consists of (i) 2,366,099 shares held by Venrock Healthcare Capital Partners III, L.P.; (ii) 236,701 shares held by VHCP Co-Investment Holdings III, LLC; and (iii) 6,397,200 shares held by Venrock Healthcare Capital Partners EG, L.P.

     

    (3)This percentage is calculated based upon 204,943,306 shares of Common Stock outstanding as of August 12, 2024 as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the “SEC”) on August 12, 2024.

     

    CUSIP No. 877619106 Page 3 of 14

     

    1.

    Names of Reporting Persons

    VHCP Co-Investment Holdings III, LLC

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) x (1)  (b) ¨

    3. SEC Use Only
    4.

    Citizenship or Place of Organization

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    5.

    Sole Voting Power

    0

    6.

    Shared Voting Power

    9,000,000 (2)

    7.

    Sole Dispositive Power

    0

    8.

    Shared Dispositive Power

    9,000,000 (2)

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

    9,000,000 (2)

    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨
    11.

    Percent of Class Represented by Amount in Row (9)

    4.4% (3)

    12.

    Type of Reporting Person (See Instructions)

    OO

           

    (1)Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G/A.

     

    (2)Consists of (i) 2,366,099 shares held by Venrock Healthcare Capital Partners III, L.P.; (ii) 236,701 shares held by VHCP Co-Investment Holdings III, LLC; and (iii) 6,397,200 shares held by Venrock Healthcare Capital Partners EG, L.P.

     

    (3)This percentage is calculated based upon 204,943,306 shares of Common Stock outstanding as of August 12, 2024 as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on August 12, 2024.

     

    CUSIP No. 877619106 Page 4 of 14

     

    1.

    Names of Reporting Persons

    Venrock Healthcare Capital Partners EG, L.P.

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) x (1)  (b) ¨

    3. SEC Use Only
    4.

    Citizenship or Place of Organization

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    5.

    Sole Voting Power

    0

    6.

    Shared Voting Power

    9,000,000 (2)

    7.

    Sole Dispositive Power

    0

    8.

    Shared Dispositive Power

    9,000,000 (2)

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

    9,000,000 (2)

    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨
    11.

    Percent of Class Represented by Amount in Row (9)

    4.4% (3)

    12.

    Type of Reporting Person (See Instructions)

    PN

           

    (1)Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G/A.

     

    (2)Consists of (i) 2,366,099 shares held by Venrock Healthcare Capital Partners III, L.P.; (ii) 236,701 shares held by VHCP Co-Investment Holdings III, LLC; and (iii) 6,397,200 shares held by Venrock Healthcare Capital Partners EG, L.P.

     

    (3)This percentage is calculated based upon 204,943,306 shares of Common Stock outstanding as of August 12, 2024 as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on August 12, 2024.

     

    CUSIP No. 877619106 Page 5 of 14

     

    1.

    Names of Reporting Persons

    VHCP Management III, LLC

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) x (1)  (b) ¨

    3. SEC Use Only
    4.

    Citizenship or Place of Organization

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    5.

    Sole Voting Power

    0

    6.

    Shared Voting Power

    9,000,000 (2)

    7.

    Sole Dispositive Power

    0

    8.

    Shared Dispositive Power

    9,000,000 (2)

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

    9,000,000 (2)

    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨
    11.

    Percent of Class Represented by Amount in Row (9)

    4.4% (3)

    12.

    Type of Reporting Person (See Instructions)

    OO

           

    (1)Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G/A.

     

    (2)Consists of (i) 2,366,099 shares held by Venrock Healthcare Capital Partners III, L.P.; (ii) 236,701 shares held by VHCP Co-Investment Holdings III, LLC; and (iii) 6,397,200 shares held by Venrock Healthcare Capital Partners EG, L.P.

     

    (3)This percentage is calculated based upon 204,943,306 shares of Common Stock outstanding as of August 12, 2024 as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on August 12, 2024.

     

    CUSIP No. 877619106 Page 6 of 14

     

    1.

    Names of Reporting Persons

    VHCP Management EG, LLC

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) x (1)  (b) ¨

    3. SEC Use Only
    4.

    Citizenship or Place of Organization

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    5.

    Sole Voting Power

    0

    6.

    Shared Voting Power

    9,000,000 (2)

    7.

    Sole Dispositive Power

    0

    8.

    Shared Dispositive Power

    9,000,000 (2)

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

    9,000,000 (2)

    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨
    11.

    Percent of Class Represented by Amount in Row (9)

    4.4% (3)

    12.

    Type of Reporting Person (See Instructions)

    OO

           

    (1)Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G/A.

     

    (2)Consists of (i) 2,366,099 shares held by Venrock Healthcare Capital Partners III, L.P.; (ii) 236,701 shares held by VHCP Co-Investment Holdings III, LLC; and (iii) 6,397,200 shares held by Venrock Healthcare Capital Partners EG, L.P.

     

    (3)This percentage is calculated based upon 204,943,306 shares of Common Stock outstanding as of August 12, 2024 as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on August 12, 2024.

     

    CUSIP No. 877619106 Page 7 of 14

     

    1.

    Names of Reporting Persons

    Shah, Nimish

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) x (1)  (b) ¨

    3. SEC Use Only
    4.

    Citizenship or Place of Organization

    United States

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    5.

    Sole Voting Power

    0

    6.

    Shared Voting Power

    9,000,000 (2)

    7.

    Sole Dispositive Power

    0

    8.

    Shared Dispositive Power

    9,000,000 (2)

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

    9,000,000 (2)

    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨
    11.

    Percent of Class Represented by Amount in Row (9)

    4.4% (3)

    12.

    Type of Reporting Person (See Instructions)

    IN

           

    (1)Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G/A.

     

    (2)Consists of (i) 2,366,099 shares held by Venrock Healthcare Capital Partners III, L.P.; (ii) 236,701 shares held by VHCP Co-Investment Holdings III, LLC; and (iii) 6,397,200 shares held by Venrock Healthcare Capital Partners EG, L.P.

     

    (3)This percentage is calculated based upon 204,943,306 shares of Common Stock outstanding as of August 12, 2024 as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on August 12, 2024.

     

    CUSIP No. 877619106 Page 8 of 14

     

    1.

    Names of Reporting Persons

    Koh, Bong

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) x (1)  (b) ¨

    3. SEC Use Only
    4.

    Citizenship or Place of Organization

    United States

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    5.

    Sole Voting Power

    0

    6.

    Shared Voting Power

    9,000,000 (2)

    7.

    Sole Dispositive Power

    0

    8.

    Shared Dispositive Power

    9,000,000 (2)

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

    9,000,000 (2)

    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨
    11.

    Percent of Class Represented by Amount in Row (9)

    4.4% (3)

    12.

    Type of Reporting Person (See Instructions)

    IN

           

    (1)Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G/A.

     

    (2)Consists of (i) 2,366,099 shares held by Venrock Healthcare Capital Partners III, L.P.; (ii) 236,701 shares held by VHCP Co-Investment Holdings III, LLC; and (iii) 6,397,200 shares held by Venrock Healthcare Capital Partners EG, L.P.

     

    (3)This percentage is calculated based upon 204,943,306 shares of Common Stock outstanding as of August 12, 2024 as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on August 12, 2024.

     

    CUSIP No. 877619106 Page 9 of 14

     

    Introductory Note: This Schedule 13G/A is filed on behalf of Venrock Healthcare Capital Partners III, L.P., a limited partnership organized under the laws of the State of Delaware (“VHCP III LP”), VHCP Co-Investment Holdings III, LLC, a limited liability company organized under the laws of the State of Delaware (“VHCP Co-Investment III”), Venrock Healthcare Capital Partners EG, L.P., a limited partnership organized under the laws of the State of Delaware (“VHCP EG”), VHCP Management III, LLC, a limited liability company organized under the laws of the State of Delaware (“VHCP Management III”), VHCP Management EG, LLC, a limited liability company organized under the laws of the State of Delaware (“VHCP Management EG” and collectively with VHCP III LP, VHCP Co-Investment III, VHCP EG and VHCP Management III, the “Venrock Entities”), Nimish Shah (“Shah”) and Bong Koh (“Koh”) in respect of the Common Stock of Taysha Gene Therapies, Inc.

     

    Item 1.
      (a)

    Name of Issuer

     

    Taysha Gene Therapies, Inc.

     
      (b)

    Address of Issuer’s Principal Executive Offices

     

    3000 Pegasus Park Drive Ste 1430

    Dallas, TX 75247

     
    Item 2.
      (a)

    Name of Person Filing

     

    Venrock Healthcare Capital Partners III, L.P.

    VHCP Co-Investment Holdings III, LLC

    Venrock Healthcare Capital Partners EG, L.P.

    VHCP Management III, LLC

    VHCP Management EG, LLC

    Nimish Shah

    Bong Koh

     
      (b)

    Address of Principal Business Office or, if none, Residence

     

        New York Office: Palo Alto Office:
         
        7 Bryant Park 3340 Hillview Avenue
        23rd Floor Palo Alto, CA 94304
        New York, NY 10018
     
      (c)

    Citizenship

     

    All of the Venrock Entities were organized in Delaware. The individuals are both United States citizens.

     
      (d)

    Title of Class of Securities

     

    Common stock, par value $0.00001 per share par value

     
      (e)

    CUSIP Number

     

    877619106

     

    CUSIP No. 877619106 Page 10 of 14

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
       
      Not applicable

     

    Item 4. Ownership
       
      (a) Amount beneficially owned as of September 30, 2024:

     

    Venrock Healthcare Capital Partners III, L.P.   9,000,000 (1)
    VHCP Co-Investment Holdings III, LLC   9,000,000 (1)
    Venrock Healthcare Capital Partners EG, L.P.   9,000,000 (1)
    VHCP Management III, LLC   9,000,000 (1)
    VHCP Management EG, LLC   9,000,000 (1)
    Nimish Shah   9,000,000 (1)
    Bong Koh   9,000,000 (1)

     

      (b) Percent of class as of September 30, 2024:

     

    Venrock Healthcare Capital Partners III, L.P.   4.4% (2)
    VHCP Co-Investment Holdings III, LLC   4.4% (2)
    Venrock Healthcare Capital Partners EG, L.P.   4.4% (2)
    VHCP Management III, LLC   4.4% (2)
    VHCP Management EG, LLC   4.4% (2)
    Nimish Shah   4.4% (2)
    Bong Koh   4.4% (2)

     

      (c) Number of shares as to which the person has, as of September 30, 2024:
         
        (i) Sole power to vote or to direct the vote:

     

    Venrock Healthcare Capital Partners III, L.P.   0 
    VHCP Co-Investment Holdings III, LLC   0 
    Venrock Healthcare Capital Partners EG, L.P.   0 
    VHCP Management III, LLC   0 
    VHCP Management EG, LLC   0 
    Nimish Shah   0 
    Bong Koh   0 

     

    CUSIP No. 877619106 Page 11 of 14

     

      (ii) Shared power to vote or to direct the vote:

     

    Venrock Healthcare Capital Partners III, L.P.   9,000,000 (1)
    VHCP Co-Investment Holdings III, LLC   9,000,000 (1)
    Venrock Healthcare Capital Partners EG, L.P.   9,000,000 (1)
    VHCP Management III, LLC   9,000,000 (1)
    VHCP Management EG, LLC   9,000,000 (1)
    Nimish Shah   9,000,000 (1)
    Bong Koh   9,000,000 (1)

     

      (iii) Sole power to dispose or to direct the disposition of:

     

    Venrock Healthcare Capital Partners III, L.P.   0 
    VHCP Co-Investment Holdings III, LLC   0 
    Venrock Healthcare Capital Partners EG, L.P.   0 
    VHCP Management III, LLC   0 
    VHCP Management EG, LLC   0 
    Nimish Shah   0 
    Bong Koh   0 

     
      (iv) Shared power to dispose or to direct the disposition of:

     

    Venrock Healthcare Capital Partners III, L.P.   9,000,000 (1)
    VHCP Co-Investment Holdings III, LLC   9,000,000 (1)
    Venrock Healthcare Capital Partners EG, L.P.   9,000,000 (1)
    VHCP Management III, LLC   9,000,000 (1)
    VHCP Management EG, LLC   9,000,000 (1)
    Nimish Shah   9,000,000 (1)
    Bong Koh   9,000,000 (1)

     

    (1)Consists of (i) 2,366,099 shares held by Venrock Healthcare Capital Partners III, L.P.; (ii) 236,701 shares held by VHCP Co-Investment Holdings III, LLC; and (iii) 6,397,200 shares held by Venrock Healthcare Capital Partners EG, L.P.
       
      VHCP Management III, LLC is the general partner of Venrock Healthcare Capital Partners III, L.P. and the manager of VHCP Co-Investment Holdings III, LLC. VHCP Management EG, LLC is the general partner of Venrock Healthcare Capital Partners EG, L.P. Messrs. Shah and Koh are the voting members of VHCP Management III, LLC and VHCP Management EG, LLC.
       
    (2)This percentage is calculated based upon 204,943,306 shares of Common Stock outstanding as of August 12, 2024 as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on August 12, 2024.

     

    Item 5. Ownership of Five Percent or Less of a Class
       
      If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following   x

     

    CUSIP No. 877619106 Page 12 of 14

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person
       
      Not applicable
     
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person
       
      Not applicable
     
    Item 8. Identification and Classification of Members of the Group
       
      Not applicable

     

    Item 9. Notice of Dissolution of Group
       
      Not applicable
     
    Item 10. Certification
       
      By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having such purpose or effect.

     

    CUSIP No. 877619106 Page 13 of 14

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: November 14, 2024

     

    Venrock Healthcare Capital Partners III, L.P.   Venrock Healthcare Capital Partners EG, L.P.
             
    By: VHCP Management III, LLC   By: VHCP Management EG, LLC
    Its: General Partner   Its: General Partner
             
    By: /s/ Sherman G. Souther   By: /s/ Sherman G. Souther
      Name: Sherman G. Souther     Name: Sherman G. Souther
      Its: Authorized Signatory     Its: Authorized Signatory
             
    VHCP Co-Investment Holdings III, LLC      
             
    By: VHCP Management III, LLC      
    Its: Manager      
             
    By: /s/ Sherman G. Souther      
      Name: Sherman G. Souther      
      Its: Authorized Signatory      
             
    VHCP Management III, LLC   VHCP Management EG, LLC
             
    By: /s/ Sherman G. Souther   By: /s/ Sherman G. Souther
      Name: Sherman G. Souther     Name: Sherman G. Souther
      Its: Authorized Signatory     Its: Authorized Signatory
             
    Nimish Shah      
           
    /s/ Sherman G. Souther      
    Sherman G. Souther, Attorney-in-fact      
             
    Bong Koh      
           
    /s/ Sherman G. Souther      
    Sherman G. Souther, Attorney-in-fact      

     

    CUSIP No. 877619106 Page 14 of 14

     

    EXHIBITS

     

    A:Joint Filing Agreement (incorporated by reference to Exhibit A to Schedule 13G filed on August 28, 2023)

     

    B:Power of Attorney for Nimish Shah (incorporated by reference to Exhibit B to Schedule 13G filed August 28, 2023)

     

    C:Power of Attorney for Bong Koh (incorporated by reference to Exhibit C to Schedule 13G filed on August 28, 2023)

     

     

    Get the next $TSHA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TSHA

    DatePrice TargetRatingAnalyst
    6/27/2024$5.00Outperform
    BMO Capital Markets
    4/9/2024$9.00Overweight
    Piper Sandler
    2/1/2023$14.00 → $1.50Buy → Hold
    Jefferies
    1/27/2023$23.00 → $3.00Overweight → Equal-Weight
    Morgan Stanley
    11/9/2022$16.00 → $3.00Buy → Neutral
    Goldman
    3/9/2022$26.00Outperform
    Robert W. Baird
    3/9/2022$26.00Outperform
    Baird
    3/1/2022$25.00Overweight
    Wells Fargo
    More analyst ratings

    $TSHA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Taysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants

      DALLAS, May 28, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (NASDAQ:TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced the pricing of an underwritten public offering of 46,868,687 shares of its common stock at a price to the public of $2.75 per share and, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase 25,858,586 shares of its common stock at an offering price of $2.749 per pre-funded warrant, in each case before underwriting discounts and commissions. All of the sec

      5/28/25 10:40:21 PM ET
      $TSHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Taysha Gene Therapies Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

      DALLAS, May 28, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (NASDAQ:TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that it has commenced an underwritten public offering of shares of its common stock and, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of its common stock. All of the securities will be offered by Taysha. Taysha also intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock offere

      5/28/25 4:02:00 PM ET
      $TSHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Taysha Gene Therapies Announces Pivotal Part B Trial Design Details for TSHA-102 in Rett Syndrome Enabled by IRSF Natural History Data and Positive Clinical Data from Part A of the REVEAL Adult/Adolescent and Pediatric Trials Evaluating TSHA-102

      Natural history data analysis established patients ≥ six years of age are in developmental plateau, with a ~0% likelihood of gaining/regaining developmental milestones across the core functional domains of Rett syndrome Written alignment from FDA supports single-arm, open label pivotal trial with primary endpoint of developmental milestone gain/regain in the developmental plateau population (≥ 6 years, intend N=15) with each patient serving as their own control 100% of patients in REVEAL Part A (N=10, 6-21 years) gained/regained ≥ one developmental milestone post-TSHA-102 with concordant improvements across multiple outcome measures; high dose consistently outperformed low dose, with dose-

      5/28/25 4:01:00 PM ET
      $TSHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TSHA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Taysha Gene Therapies Inc.

      SC 13G/A - Taysha Gene Therapies, Inc. (0001806310) (Subject)

      11/14/24 5:51:11 PM ET
      $TSHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Taysha Gene Therapies Inc.

      SC 13G/A - Taysha Gene Therapies, Inc. (0001806310) (Subject)

      11/14/24 5:46:12 PM ET
      $TSHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Taysha Gene Therapies Inc.

      SC 13G - Taysha Gene Therapies, Inc. (0001806310) (Subject)

      11/14/24 9:40:52 AM ET
      $TSHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TSHA
    Leadership Updates

    Live Leadership Updates

    See more
    • Taysha Gene Therapies Reports Full-Year 2020 Financial Results and Provides a Corporate Update

      DALLAS--(BUSINESS WIRE)--Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, today reported financial results for the full-year ended December 31, 2020 and provided a corporate update. “In 2020, we successfully completed one of the fastest seed to IPOs in biotech history and made significant strides in advancing our pipeline initiatives, next-generation technology platforms and manufacturing strategy,” said RA Session II, President, Founder and CEO o

      3/3/21 7:00:00 AM ET
      $TSHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Taysha Gene Therapies Continues to Add Significant Gene Therapy Expertise to Leadership Team with the Appointment of Chief Legal Officer and Chief People Officer

      DALLAS--(BUSINESS WIRE)--Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system in both rare and large patient populations, today announced new additions to its leadership team with the appointments of Timothy J. Douros, J.D., as Chief Legal Officer and Corporate Secretary and Tracy M. Porter, M.Ed., SPHR, as Chief People Officer. Mr. Douros will lead all aspects of the company’s legal organization. Ms. Porter will oversee all aspects of human resources, including operations, talent acquisition and employee development.

      1/26/21 7:00:00 AM ET
      $TSHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TSHA
    Financials

    Live finance-specific insights

    See more
    • Taysha Gene Therapies Reports First Quarter 2025 Financial Results and Provides Corporate Update

      Obtained written alignment from the FDA on key elements of TSHA-102 pivotal Part B trial design and next steps on enabling study initiation The FDA advised the Company to submit pivotal Part B trial protocol and associated statistical analysis plan as an amendment to the IND application, eliminating the need for formal end-of-phase meeting and potentially expediting study initiation and registration; IND amendment submission expected in Q2 2025 High dose and low dose of TSHA-102 continue to be generally well tolerated with no treatment-related SAEs or DLTs in the pediatric, adolescent and adult patients treated (high dose, n=6; low dose, n=4) across both REVEAL trials as of April 10, 2025,

      5/15/25 8:00:00 AM ET
      $TSHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Taysha Gene Therapies to Release First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 15

      DALLAS, May 08, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (NASDAQ:TSHA), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that it will report its financial results for the first quarter ended March 31, 2025, and host a corporate update conference call and webcast on Thursday, May 15, 2025, at 8:30 AM Eastern Time. Conference Call DetailsThursday, May 15, at 8:30 AM Eastern Time / 7:30 AM Central TimeToll Free: 877-407-0792International: 201-689-8263Conference ID: 13753490Webcast: https://ir.tayshagtx.com/news-events/events-presentations

      5/8/25 4:05:00 PM ET
      $TSHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Taysha Gene Therapies Reports Full-Year 2024 Financial Results and Provides Corporate Update

      High dose and low dose of TSHA-102 continue to be generally well tolerated with no treatment-related SAEs or DLTs in all pediatric, adolescent and adult patients treated (high dose, n=6; low dose, n=4) across both REVEAL trials as of February 2025 data cutoff Completed dosing of the 10 patients in Part A of both REVEAL trials; maturing dataset continues to support advancement toward pivotal Part B trial Productive ongoing discussions with the FDA to solidify regulatory pathway for TSHA-102; update on pivotal trial design expected in H1 2025 Clinical data from cohort two (high dose) and cohort one (low dose) of both REVEAL trials expected in H1 2025 Conference call and live webcast today

      2/26/25 8:00:00 AM ET
      $TSHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TSHA
    SEC Filings

    See more
    • SEC Form 8-K filed by Taysha Gene Therapies Inc.

      8-K - Taysha Gene Therapies, Inc. (0001806310) (Filer)

      5/29/25 4:38:45 PM ET
      $TSHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 424B5 filed by Taysha Gene Therapies Inc.

      424B5 - Taysha Gene Therapies, Inc. (0001806310) (Filer)

      5/29/25 4:32:50 PM ET
      $TSHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: Taysha Gene Therapies Inc. filed SEC Form 8-K: Regulation FD Disclosure

      8-K/A - Taysha Gene Therapies, Inc. (0001806310) (Filer)

      5/29/25 6:02:26 AM ET
      $TSHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TSHA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Amendment: SEC Form 4 filed by CHIEF FINANCIAL OFFICER Alam Kamran

      4/A - Taysha Gene Therapies, Inc. (0001806310) (Issuer)

      4/10/25 4:15:13 PM ET
      $TSHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • CHIEF FINANCIAL OFFICER Alam Kamran covered exercise/tax liability with 29,843 shares, decreasing direct ownership by 2% to 1,242,094 units (SEC Form 4)

      4 - Taysha Gene Therapies, Inc. (0001806310) (Issuer)

      3/13/25 4:15:05 PM ET
      $TSHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Executive Officer Nolan Sean P. was granted 892,500 shares, increasing direct ownership by 75% to 2,078,358 units (SEC Form 4)

      4 - Taysha Gene Therapies, Inc. (0001806310) (Issuer)

      1/3/25 5:38:40 PM ET
      $TSHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TSHA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • BMO Capital Markets initiated coverage on Taysha Gene Therapies with a new price target

      BMO Capital Markets initiated coverage of Taysha Gene Therapies with a rating of Outperform and set a new price target of $5.00

      6/27/24 7:52:29 AM ET
      $TSHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Piper Sandler initiated coverage on Taysha Gene Therapies with a new price target

      Piper Sandler initiated coverage of Taysha Gene Therapies with a rating of Overweight and set a new price target of $9.00

      4/9/24 8:33:01 AM ET
      $TSHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Taysha Gene Therapies downgraded by Jefferies with a new price target

      Jefferies downgraded Taysha Gene Therapies from Buy to Hold and set a new price target of $1.50 from $14.00 previously

      2/1/23 6:22:31 AM ET
      $TSHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TSHA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Manning Paul B bought $2,999,999 worth of shares (1,333,333 units at $2.25) (SEC Form 4)

      4 - Taysha Gene Therapies, Inc. (0001806310) (Issuer)

      7/1/24 8:00:07 AM ET
      $TSHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Manning Paul B bought $163,000 worth of shares (100,000 units at $1.63) (SEC Form 4)

      4 - Taysha Gene Therapies, Inc. (0001806310) (Issuer)

      11/20/23 7:35:02 AM ET
      $TSHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care